Please login to the form below

Not currently logged in
Email:
Password:

In the Wild

This page shows the latest In the Wild news and features for those working in and with pharma, biotech and healthcare.

FDA halts study of Teva and Regeneron's pain drug fasinumab

FDA halts study of Teva and Regeneron's pain drug fasinumab

However, the updated results revealed what might be a dose-dependent increase in the risk of arthropathy with the drug. ... view the candidates still in trials as wild cards, potentially offering big rewards but also a having a high risk of failure.

Latest news

  • NICE backs BMS' Opdivo for melanoma NICE backs BMS' Opdivo for melanoma

    We welcome [the] decision from NICE, which is positive news for melanoma patients in the UK," said Johanna Mercier, general manager of BMS in the UK and Ireland. ... approval. The green light means that the cancer immunotherapy combination can be used in

  • New behavioural science comms consultancy launches New behavioural science comms consultancy launches

    New behavioural science comms consultancy launches. In the Wild will be led by managing director Andrew Martello. ... In the Wild's managing director Andrew Martello said: “ Our clients are innovators in the pharmaceutical industry who see the untapped

  • Erbitux betters Avastin in bowel cancer subgroup Erbitux betters Avastin in bowel cancer subgroup

    However, new data presented at the Congress suggests that Merck's drug may be superior in the subset of patients with RAS wild-type mCRC – a form of mCRC associated with ... overall survival and may in part explain why we are seeing the overall

  • Information seen as main future health issue

    All attendees highlighted the importance of behaviour change in the public, with individuals becoming empowered to make efforts and decisions regarding their own health. ... In all sessions, however, the most pressing matter in information proliferation

  • Tamiflu boosts Roche sales rise

    Roche is riding high on the back of strong demand for antiviral, Tamiflu, after reporting a 20 per cent rise in third quarter sales to SwFr 10.47bn ($8.23bn), beating ... ìThis is the wild card in the pack, î Roche pharmaceuticals unit head, William

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics